Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

ent options for physicians and their patients." 

About Lung Cancer

Lung cancer is the second most common cancer and kills more people than any other cancer.  In 2010, approximately 222,250 new cases of lung cancer will be diagnosed in the United States, with 157,300 Americans dying from the disease.   NSCLC is the most common form of lung cancer, accounting for about 85% of all lung cancers.(4)  Lung cancer remains an area of high unmet need, especially in its advanced stages where it is particularly aggressive and patients have limited treatment options. There is no FDA-approved therapy for patients with advanced lung cancer who have failed chemotherapy and progressed after treatment with an EGFR TKI.

About Afatinib's Clinical Trial Program: LUX Trial Program

The LUX trial program is a comprehensive and robust program that comprises more than 10 trials conducted across the globe, investigating afatinib in a variety of different solid tumor types, including NSCLC, breast and head and neck cancer.

LUX-Lung 1 is a phase IIb/III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and first-generation EGFR TKIs, erlotinib or gefitinib.

LUX-Lung 2 is a phase II trial evaluating afatinib in NSCLC patients with EGFR mutations, either treatment naïve or after one line of chemotherapy.

In two ongoing global phase III trials, LUX-Lung 3 and LUX-Lung 6, the efficacy and safety of afatinib is compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations in different geographical regions.

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Stryker brand ambassadors Fred Funk and Hal ... Tour event near Minneapolis, MN , which begins ... Stryker is the official joint replacement products company of the PGA ... st through Sunday, August 3 rd , fans will be ... destination located in the Pioneer Press Expo tent located near the ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July ... ARNA ) announced today that an article based ... of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, ... was recently published in the online issue of Obesity ... The objective of these analyses was to identify whether there ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Mylan Inc. (Nasdaq: MYL ) today announced that it has ... amount of 7.625% Senior Notes due 2017 and $700 million ... is using $1.0 billion of the net proceeds from ... loans, thereby reducing senior secured leverage and extending the maturity profile ...
... SHENZHEN, China , May 19 /PRNewswire-Asia/ ... Medical" or the "Company"), a leading manufacturer of,medical dressings, ... consumer products industries, announced today that in,connection with the ... common stock, par value $0.001 per share, ...
Cached Medicine Technology:Mylan Announces Completion of Senior Notes Offering 2Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 2Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 3Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 4
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... time in a garden might help soothe the agitation that ... Looking at 17 past studies, British researchers found evidence that ... help soothe some dementia patients, anxiety. The study authors ... a tough subject to study -- and the evidence of ...
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for ... not be those that can proliferate the fastest, researchers ... in an advance online publication of the journal ... the treatment of cancer with precision medicines, the study ... are truly driving the tumor,s growth and metastasis and ...
(Date:7/30/2014)... July 30, 2014 According to ... Machine Vision Market by Technology (ICS, MES, ERP, ... Components (Camera, FGOL), Application (Process, Discrete) - Global ... by MarketsandMarkets, the Mexican market is expected to ... by 2020. , Browse 70 market data Tables ...
(Date:7/30/2014)... July 30, 2014 Everyone knows that the ... basically everyone. Whether people are looking for something to buy, ... a dentist, the internet is pretty much always going to ... Dental in Lauderdale Florida is so happy to announce the ... web presence into the modern age. Whether a person wants ...
(Date:7/30/2014)... 2014 Shabaikai is an ambitious historical ... the Pomo Indians located on the shores of Russian ... Shabaikai, meaning ‘crooked snake’. Clarkson takes the reader into ... violence of prohibition and organized crime, providing a glimpse ... the most powerful men in the world convene the ...
Breaking Medicine News(10 mins):Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2
... Clemson University researcher Julia Frugoli has received $132,769 as ... from the National Science Foundation to continue her study ... other to control their growth and development. The ... College of Agriculture, Forestry & Life Sciences, genetics and ...
... , MONDAY, May 14 (HealthDay News) -- In black ... arteries in the eye,s retina (retinal arteriolar narrowing) is ... study finds. , "Retinal arteriolar narrowing has long been ... hypertension [high blood pressure] and cardiovascular disease," Dr. Monique ...
... Philadelphia, PA, May 14, 2012 Health professionals commonly say, ... but is there any scientific basis for the advice? ... your past experience with needle pricks, along with information you ... is published in the May issue of Pain . ...
... A new type of artificial eye system could one day ... to degenerative eye diseases such as macular degeneration, according to ... tiny solar panel-like cells that are surgically placed beneath the ... with a miniature camera, and a pocket PC that processes ...
... examining the effects of resveratrol on individuals with mild ... as more than two dozen academic institutions recruit volunteers ... Ph.D., director of Georgetown University Medical Center,s Memory Disorders ... Resveratrol is a compound found in red grapes, ...
... (HealthDay News) -- Doing more repetitions with less weight ... training with heavy weights, a new Canadian study indicates. ... yourself to the point of fatigue, according to the ... examined how different combinations of weight loads and repetitions ...
Cached Medicine News:Health News:Clemson professor awarded nearly $600,000 4-year grant to study language of plants 2Health News:To avoid pain during an injection, look away 2Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Georgetown physician leads national resveratrol study for Alzheimer's disease 2Health News:Georgetown physician leads national resveratrol study for Alzheimer's disease 3Health News:With Weights, You Can Lighten Your Load 2
... PreVue B. Burgdorferi Antibody Detection Assay is ... the qualitative presumptive (first step) detection of ... in human serum or whole blood. Rapid ... accuracy make the Wampole PreVue B. burgdorferi ...
... to U.S. and international engineering and ... Screw and Plating System* provides seamless ... of use for open reduction internal ... TC-100 system works well beyond the ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... international engineering and design specifications, Smith ... System* provides seamless integration with existing ... open reduction internal fixational procedures (AO ... well beyond the standard, providing a ...
Medicine Products: